Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer's disease

Current Neurovascular Research

Volumn 10, Issue 4, 2013, Pages 297-303

  Marksteiner, Josef ^a   Humpel, Christian ^a,b  

^a Tilak Hall in Tirol   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Alzheimer; Amyloid precursor protein; APP; BACE1; Biomarker; Diagnosis; ELISA; Platelets

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; SECRETED AMYLOID PRECURSOR PROTEIN ALPHA; SECRETED AMYLOID PRECURSOR PROTEIN BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN STABILITY; THROMBOCYTE; WESTERN BLOTTING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 84888235936     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/15672026113109990022     Document Type: Article

References (44)

1. Desai AK, Grossberg GT. Diagnosis and treatment of Alzheimerś disease. Neurology 2005; 64: 34-9.
2. McKeel DW, Price JL, Miller JP, et al. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. J Neuropathol Exp Neurol 2004; 63: 1028-37.
3. Fradinger EA, Bitan G. En route to early diagnosis of Alzheimerś disease-are we there yet? Trends Biotechnol 2005; 23: 531-3.
4. Blennow K. CSF biomarkers for Alzheimerś disease: use in erarly diagnosis and evaluation of drug treatment. Expert Rev. Mol. Diagn 2005; 5: 661-72.
5. Zetterberg H, Blennow K, Hanse E. Amyloid β and APP as biomarkers for Alzheimers disease. Exp Gerontol 2010; 45: 23-9.
6. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol 2010; 45(1): 30-40.
7. Blasko I, Lederer W, Oberbauer H, et al. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 2006; 21: 9-15.
8. Humpel C. Identifying and validating biomarkers for diagnosing Alzheimer's disease. Trends Biotechnol 2010; 29(1): 26-32.
9. Pelech, S. Biomarker identification for diagnosis of Alzheimers disease, Expert Opin Med Diagn 2008; 2: 577-91.
10. Hochstrasser T, Marksteiner J, Defrancesco M, Deisenhammer EA, Kemmler G, Humpel C. Two blood monocytic biomarkers (CCL15 and p21) combined with Mini-Mental State Examination discriminates Alzheimer's disease patients from healthy controls. Dement Geriatr Cogn Disord Extra 2011b; 1(1): 297-309.
11. Hochstrasser T, Ehrlich D, Marksteiner J, Sperner-Unterweger B, Humpel C. Matrix metalloproteinase-2 and epidermal growth factor are decreased in platelets of Alzheimer patients. Curr Alzheimer Res 2011a; 9(8): 982-9.
12. Padovani A, Pastorino L, Borroni B, et al. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology 2001; 57: 2243-8.
13. Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A. Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 2010; 45: 53-6.
14. Borroni B, Perani D, Broli M, et al. A Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis. J Neurol 2005; 252: 1359-62.
15. Borroni B, Di Luca M, Padovani A. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful? Eur J Pharmacol 2006; 545: 73-80.
16. Vignini A, Sartini D, Morganti S, et al. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. Int J Immunopathol Pharmacol 2011; 24: 529-34.
17. Casoli T, Di Stefano G, Balietti M, Solazzi M, Giorgetti B, Fattoretti P. Peripheral inflammatory biomarkers of Alzheimerś disease: the role of platelets. Biogerontology 2010; 11: 627-33.
18. Bush Al, Martis RN, Rumble B, et al. The amyloid precursor protein of Alzheimerś disease is released by human platelets. J Biol Chem 1990; 265:15977-83.
19. Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL. Secretion of Alzheimer's disease Aß-amyloid peptide by activation of human platelets. Lab Invest 1998; 78: 461-9.
20. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the principal source of amyloid β-peptide in human blood. Biochem Biophys Res Commun 1995; 213: 96-103.
21. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 2010; 90, 465-94.
22. Li QX, Fuller SJ, Beyreuther K, Masters CL. The amyloid precursor protein of Alzheimer disease in human brain and blood. J Leukoc Biol.1999; 66:567-74.
23. Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimerś disease amyloid precursor protein in brain and platelets. J Neurosci Res 2003; 74:386-92.
24. Li QX, Berndt MC, Bush AI, et al. Membrane-associated forms of the β A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood 1994; 84:133-42.
25. Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci 2006; 240: 53-8.
26. Skovronsky DM, Lee VM, Praticò D. Amyloid precursor protein and amyloid β peptide in human platelets. Role of cyclooxygenase and protein kinase C J Biol Chem. 2001; 20: 17036-43.
27. Kitazume S, Yoshihisa A, Yamaki T, et al. Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. J Biol Chem. 2012; 287(48): 40817-25.
28. Di Luca M, Pastorino L, Bianchetti A, et al. Differential level of plateletamyloid β precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 1998; 55: 1195-2000.
29. Li QX, Evin G, Small DH, Multhaup G, Beyreuther K, Masters CL. Proteolytic processing of Alzheimer's disease β A4 amyloid precursor protein in human platelets. J Biol Chem 1995; 270: 14140-7.
30. Ehrlich D, Hochstrasser T, Humpel C. Effects of oxidative stress on amyloid precursor protein processing in rat and human platelets. Platelets 2013; 24(1): 26-36.
31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
32. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 1992; 58: 1985-92.
33. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
34. Yesavage JA, Brink TL, Rose TL, et al. Development and Validation of A Geriatric Depression Screening Scale-A Preliminary-Report. J Psychiatr Res 1983; 17: 37-49.
35. Blasko I, Jungwirth S, Jellinger K, et al. Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort. J Psychiatr Res. 2008; 42(11): 946-55.
36. Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT. Role of the APP non-amyloidogenic signaling pathway and targeting α-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr Med Chem 2007; 14: 2848-64.
37. Zainaghi IA, Talib LL, Diniz BS, Gattaz WF, Forlenza OV. Reducedplatelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease. J Neural Transm.2012; 119(7): 815-9.
38. Obregon D, Hou H, Deng J, et al. Soluble amyloid precursor protein-β modulates β-secretase activity and amyloid-β generation. Nat Commun. 2012; 3:777.
39. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. β-Secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002; 59: 1381-9.
40. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann Neurol 2002; 51: 783-6.
41. Li R, Lindholm K, Yang LB, et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 2004; 101: 3632-7.
42. Tamagno E, Bardini P, Obbili A, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002; 10: 279-88.
43. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW. Increased β-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 2004; 1009: 1-8.
44. Zhang X, Zhou K, Wang R, et al. Hypoxia-inducible factor 1α (HIF-1α)-mediated hypoxia increases BACE1 expression and β-amyloid generation. J Biol Chem 2007; 282: 10873-80.